Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 1;19(10):861-871.
doi: 10.2217/pgs-2018-0023. Epub 2018 Jun 19.

From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation

Naji C Salloum  1 , Erica L F Buchalter  1 , Swati Chanani  1 , Gemma Espejo  1 , Mahjabeen S Ismail  1 , Randy O Laine  2 , Maysaa Nageeb  1 , A Benjamin Srivastava  1 , Nicholas Trapp  1 , Ludwig Trillo  1 , Erica Vance  1 , Michael Wenzinger  1 , Sarah M Hartz  1 , Sean P David  3 , Li-Shiun Chen  1
Affiliations

From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation

Naji C Salloum et al. Pharmacogenomics. .

Abstract

Smoking cessation treatment outcomes may be heavily influenced by genetic variations among smokers. Therefore, identifying specific variants that affect response to different pharmacotherapies is of major interest to the field. In the current study, we systematically review all studies published in or after the year 1990 which examined one or more gene-drug interactions for smoking cessation treatment. Out of 644 citations, 46 articles met the inclusion criteria for the systematic review. We summarize evidence on several genetic polymorphisms (CHRNA5-A3-B4, CYP2A6, DBH, CHRNA4, COMT, DRD2, DRD4 and CYP2B6) and their potential moderating pharamacotherarpy effects on patient cessation efficacy rates. These findings are promising and call for further research to demonstrate the effectiveness of genetic testing in personalizing treatment decision-making and improving outcome.

Keywords: nicotine replacement therapy; pharmacogenetics; precision medicine; smoking cessation.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This research was supported by R01 DA038076, and K08 DA030398 (Chen LS) from the National Institute on Drug Abuse, P30 CA091842-16S2 from the National Caner Institute, U54 MD010724 (David SP), and sub-award KL2 RR024994 (Chen LS) from the National Center for Research Resources. The authors have no other relevant affiliations or financialinvolvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Flowchart of study inclusion.
RCT: Randomized controlled trial.
See this image and copyright information in PMC

References

    1. Schroeder SA. New evidence that cigarette smoking remains the most important health hazard. N. Engl. J. Med. 2013;368(4):389–390. - PubMed
    1. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N. Engl. J. Med. 2013;368(4):351–364. - PMC - PubMed
    1. Whiteford HA, Baxter AJ. The global burden of disease 2010 study: what does it tell us about mental disorders in Latin America? Rev. Bras. Psiquiatr. 2013;35(2):111–112. - PubMed
    1. Knopik VS, Maccani MA, Francazio S, McGeary JE. The epigenetics of maternal cigarette smoking during pregnancy and effects on child development. Dev. Psychopathol. 2012;24(4):1377–1390. - PMC - PubMed
    1. 2008 PHS Guideline Update Panel La and Staff. Treating tobacco use and dependence: 2008 Update US Public Health Service Clinical Practice Guideline executive summary. Respir. Care. 2008;53(9):1217–1222. - PubMed

Publication types

LinkOut - more resources